Vir Biotechnology, Inc. (VIR) News
Follow Vir Biotechnology, Inc. (VIR) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 7 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Vir Biotechnology Prices $150 Million Stock Offering at $10 Per Share
Vir Biotechnology agreed to sell 15 million common shares at $10 each for $150 million in gross proceeds. Underwriters have a 30-day option to purchase up to 2.25 million additional shares.
EQUITY | Nov 16, 2026, 11:27 AM UTC
L
Vir Biotechnology Stock Gains on Positive Trial Results for Chronic Hepatitis Treatment
By Kelly CloonanShares of Vir Biotechnology rose after the company reported positive results from two studies for a chronic hepatitis treatment.The stock gained 16% to $14.19 in premarket trading on Monday. At Friday's m
EQUITY | Nov 09, 2026, 11:39 AM UTC
M
Vir Biotechnology Shares Jump 11% to $12.21 on Friday
Vir Biotechnology shares rose 11% to $12.21 on Friday, following positive hepatitis delta trial results.
EQUITY | Nov 09, 2026, 06:00 AM UTC
M
Vir Biotechnology beats Q3 EPS estimates by $0.18, misses on revenue
Vir reported a Q3 loss of $0.57 per share, excluding non-recurring items, $0.18 better than the FactSet estimate; revenue missed estimates.
EQUITY | Nov 04, 2026, 09:31 PM UTC
M
Vir Biotechnology Signs Gilead Deal to Develop Solid-Tumor T-Cell Engagers
Vir said it signed an agreement with Gilead Sciences to discover and develop next-generation T-cell engagers for solid tumors. Vir shares traded 8.2% higher at $11.48 ahead of the morning bell.
EQUITY | Oct 14, 2026, 01:45 PM UTC
M
Vir Biotechnology Signs Gilead Deal Worth Up to $135M Near-Term
Vir will receive $90 million upfront—$65 million in cash and $25 million in equity at a 30% premium—and up to $45 million in near-term preclinical milestones. The collaboration covers discovery of three PRO-XTEN dual-mas
EQUITY | Oct 14, 2026, 12:31 PM UTC
L
VIR Vir Biotechnology announces Chief Financial Officer transition Vir Biotechnology - appoints Brent sabatini as interim Principal financia
VIR Vir Biotechnology announces Chief Financial Officer transition Vir Biotechnology - appoints Brent sabatini as interim Principal financial officer effective July 23 - Jason o’byrne to leave Vir Biotechnology, remains
ENERGY | Jul 24, 2026, 12:30 PM UTC